Rahul Banerjee, MD, FACP
@rahulbanerjeemd.bsky.social
Assistant Professor at Fred Hutch Cancer Center (Seattle, WA, USA) specializing in multiple myeloma #MMsm and CAR-T therapy.
My research focus: improving the patient experience in myeloma.
COI: https://coi.asco.org/share/VU2-FHC3/Rahul%20Banerjee
My research focus: improving the patient experience in myeloma.
COI: https://coi.asco.org/share/VU2-FHC3/Rahul%20Banerjee
Thank you Yan!!
May 22, 2025 at 3:09 AM
Thank you Yan!!
Reposted by Rahul Banerjee, MD, FACP
@rahulbanerjeemd.bsky.social @fredhutch.bsky.social @mountsinainyc.bsky.social @mountsinai.bsky.social
ashpublications.org/bloodadvance...
ashpublications.org/bloodadvance...
Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma
Rahul Banerjee, Alicia Richards, Shonali Midha, Aimaz Afrough, Faiz Anwer, Djordje Atanackovic, Shebli Atrash, Veronika Bachanova, Amer M. Beitinjaneh, Evg
ashpublications.org
March 17, 2025 at 11:49 PM
Reposted by Rahul Banerjee, MD, FACP
Talquetamab plus Teclistamab in Multiple Myeloma (RedirecTT-1 study) nej.md/4iZNYTY
Driver Mutations in Myelofibrosis (single-group, single-center study) nej.md/4fQNdKn
Driver Mutations in Myelofibrosis (single-group, single-center study) nej.md/4fQNdKn
January 9, 2025 at 2:14 PM
Talquetamab plus Teclistamab in Multiple Myeloma (RedirecTT-1 study) nej.md/4iZNYTY
Driver Mutations in Myelofibrosis (single-group, single-center study) nej.md/4fQNdKn
Driver Mutations in Myelofibrosis (single-group, single-center study) nej.md/4fQNdKn